Full-Time

Associate Chief of Staff

Updated on 9/3/2026

Coherus BioSciences

Coherus BioSciences

201-500 employees

Develops and commercializes biosimilar biologics

Compensation Overview

$125k - $150k/yr

Redwood City, CA, USA

In Person

Bachelor's, MBA

Category
Business & Strategy (1)
Required Skills
Microsoft Office
Word/Pages/Docs
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to Coherus BioSciences

See people who can refer or advise you

Requirements
  • An MBA and a bachelor's degree are required; a bachelor's degree in business, finance, life sciences, or a related field is preferred.
  • Approximately 3-6 years of relevant experience in management or strategy consulting, life sciences, corporate strategy, business operations, business development, investor relations, finance, or a comparable fast-paced environment.
  • Demonstrated ability to independently manage complex projects and produce executive-level analyses, presentations, and written communications.
  • Strong proficiency in Microsoft Office, particularly PowerPoint, Excel, Word, and Outlook.
  • Ability to travel periodically based on business needs.
  • Ability to protect highly confidential and sensitive information and recognize when escalation is appropriate.
  • Ability to build trust, read interpersonal dynamics, and work effectively with the CEO, senior executives, Board members, and colleagues at all levels.
  • Ability to make sound, timely decisions in ambiguous situations using available information and judgment, including knowing when to act independently and when to seek input.
  • Analytical, project management, and problem-solving skills, with the ability to manage multiple priorities and senior stakeholders.
  • Written and verbal communication skills and the ability to distill complex information into concise, decision-oriented materials.
  • Strong organization, proactivity, accountability, attention to detail, follow-through, and responsiveness to urgent business needs, including occasional availability outside normal working hours.
  • Willingness to engage in both strategic work and essential administrative execution.
  • Intellectual curiosity, business judgment, and interest in developing toward a broader operating or functional leadership role.
Responsibilities
  • Partner with the Chief of Staff before the leave to develop business context, establish relationships, and complete a structured transition of priorities, processes, and key stakeholder responsibilities.
  • During the approximately three-month leave, maintain the operating cadence of the Executive Office and coordinate CEO-facing priorities, critical meetings, communications, and follow-up.
  • Prepare the CEO and senior leaders for key decisions and engagements through concise analyses, briefing materials, presentations, agendas, and pre-reads.
  • Attend selected executive and cross-functional meetings; capture decisions, actions, and owners; drive follow-through; and escalate sensitive issues appropriately.
  • Support the return transition by maintaining clear documentation and preparing an effective handback of responsibilities and open items.
  • Manage scheduling for the CEO and Chief of Staff, including coordinating internal and external meetings, resolving conflicts, and ensuring appropriate preparation and follow-up.
  • Coordinate business travel for the CEO, including itineraries, transportation, accommodations, and related logistics.
  • Prepare and submit expense reports accurately and on time.
  • Coordinate logistics for Board and committee meetings, leadership meetings, investor engagements, conferences, offsites, and other important executive activities.
  • Maintain organized calendars, records, trackers, and Executive Office materials while handling confidential, sensitive, and potentially market-moving information with discretion.
  • Anticipate needs, respond to changing priorities, and resolve administrative or logistical issues with minimal direction.
  • Perform strategic, operational, and administrative work as needed in support of the Executive Office.
  • Lead priority cross-functional initiatives from planning through execution, including workplans, milestones, stakeholder alignment, status reporting, and issue resolution.
  • Synthesize complex information into clear, decision-oriented recommendations for the Chief of Staff, CEO, and senior leadership team.
  • Own defined Executive Office workstreams and recurring processes, including trackers for key commitments, decisions, and deliverables.
  • Identify and implement improvements to Executive Office processes, information flow, and meeting effectiveness.
  • Provide flexible support for high-priority and time-sensitive assignments as business needs evolve.
  • Support Board and committee meetings, leadership meetings, and offsites, including materials, logistics, executive preparation, and follow-up.
  • Prepare executives for investor and analyst meetings, conferences, external presentations, and other high-stakes engagements.
  • Partner with Investor Relations, Finance, and other functions on earnings materials, corporate presentations, briefing books, key messages, Q&A, and selected external communications.
  • Monitor Company, peer, industry, and investor developments and summarize implications for internal stakeholders.
  • Serve as a trusted and discreet point of contact for executives, Board members, consultants, and other senior stakeholders.
  • Continue to report to and partner with the Chief of Staff across strategic initiatives, executive communications, Board and investor-related activities, and cross-functional execution following the leave period.
  • Take increasing ownership of substantive workstreams and projects, with scope expanding based on performance, capabilities, and Company priorities.
  • Build broad functional exposure and readiness for a potential future transition into Commercial, Business Development, Investor Relations, or Finance.
Desired Qualifications
  • Experience in a publicly traded biotechnology or pharmaceutical company.

Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines. These products are created through biotechnology to match the safety and effectiveness of the original biologics while offering lower prices. Coherus’ products are designed to provide patients and healthcare systems with more affordable access to essential biologic treatments and to offset rising healthcare costs. The company differentiates itself by focusing on high-quality biosimilars and a rigorous regulatory pathway to ensure similar efficacy and safety to the originals, enabling broader adoption among providers, hospitals, and patients. Its goal is to improve patient lives by expanding access to life-changing biologic medicines and making treatments more affordable.

Company Size

201-500

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2010

Get referred to Coherus BioSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 debt refinancing extended maturities to 2031 and lowered interest burden.
  • June 2026 Zumutor collaboration broadens LOQTORZI combinations into multiple solid tumors.
  • Second-quarter 2026 results and 2025 sales growth showed LOQTORZI traction after the biosimilar exit.

What critics are saying

  • LOQTORZI depends on nasopharyngeal carcinoma; weak expansion stalls 2028 revenue targets.
  • Tagmokitug and casdozokitug remain clinical-stage; a failed 2026 readout crushes valuation.
  • If LOQTORZI uptake disappoints, Coherus burns cash and risks another dilutive financing.

What makes Coherus BioSciences unique

  • LOQTORZI gives Coherus a commercial oncology franchise, not a pure biosimilar story.
  • Coherus owns U.S. rights to toripalimab and combinations like Tagmokitug and casdozokitug.
  • Management exited biosimilars in 2025, concentrating capital on novel immuno-oncology development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive base salary

Target bonus based on performance

stock options

Medical, dental, & vision coverage

PTO

401(k) plan

FSA

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

-2%
Minichart
Aug 17th, 2026
Coherus Oncology secures $55M term loan, extends debt maturity to 2031

Coherus Oncology has secured a $55 million senior secured term loan to refinance existing debt and extend its maturity timeline. The company signed the agreement with Innovatus Life Sciences Lending Fund I and other lenders on 12 August 2026, drawing the full amount two days later. The new loan matures in August 2031, extending the previous May 2029 deadline beyond anticipated product launches. It carries a floating interest rate of 4.15% plus the greater of Prime Rate or 6.75%, lower than the prior facility's 8.0% plus three-month SOFR. The facility includes a 36-month interest-only period, potentially extendable to 48 months upon meeting revenue and market capitalisation targets. Additional tranches of $25 million and $20 million remain available under certain conditions.

BioPatrika
Jun 24th, 2026
Coherus and Zumutor launch Phase 1 trial of ZM008 and LOQTORZI combination therapy.

Coherus and Zumutor launch Phase 1 trial of ZM008 and LOQTORZI combination therapy. June 24, 2026 Coherus and Zumutor Biologics announce clinical collaboration to evaluate ZM008 in combination with LOQTORZI(R)(toripalimab-tpzi). - First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor. Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor (Trial ID: NCT06451497). The study will enroll patients with colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers, among other solid tumors. "We are excited to partner with Zumutor Biologics on the development of LOQTORZI with ZM0008 as a novel combination treatment for cancer patients in this Phase 1 study," said Theresa LaVallee, Ph.D., Chief Scientific and Development Officer at Coherus Oncology. "This collaboration is another example of our strategy to expand potential LOQTORZI indications beyond NPC and strengthen the clinical data package in the US through cost-efficient drug supply agreements, evaluating LOQTORZI with novel mechanisms in prioritized tumor types such as NSCLC, HNSCC, and others." ZM008, discovered using Zumutor's proprietary fully human monoclonal antibody library INABLR(R), has demonstrated a favorable safety profile, with no dose-limiting toxicities or anti-drug antibodies. In an ongoing monotherapy study, ZM008 has shown clinical benefit in metastatic patients previously treated with immune checkpoint inhibitors. Targeting complementary adaptive and innate immune pathways can unlock meaningful clinical benefit, particularly in hard-to-treat "cold tumors" that remain less responsive to current immunotherapies. "This Phase 1 study will evaluate ZM008 in combination with LOQTORZI and will generate key insights into response mechanisms, identify predictive biomarkers, and refine patient selection strategies to accelerate personalized therapies," said Maloy Ghosh, Ph.D., Chief Scientific Officer of Zumutor. The trial will evaluate safety, tolerability, and the recommended dose of ZM008, enrolling up to 45 patients across dose-escalation and expansion cohorts in the United States. "The initiation of combination studies of ZM008 with toripalimab, from Coherus Oncology, represents a pivotal milestone for our lead program," said Kavitha Iyer Rodrigues, CEO of Zumutor Biologics Inc. "Building on encouraging early clinical data, this advancement strengthens our conviction in ZM008's potential to deliver a differentiated and meaningful immunotherapy option for patients with difficult-to-treat cancers and underscores our commitment to accelerating its clinical development." Under the terms of the clinical trial collaboration and supply agreement, Coherus Oncology will provide LOQTORZI to Zumutor, which will be the sponsor of the Phase 1 clinical combination trial. Zumutor and Coherus each retain all commercial rights to their respective compounds, as monotherapies or combination therapies. About Zumutor Biologics Inc. Zumutor Biologics Inc. is a clinical-stage biotechnology company pioneering next-generation immunotherapies by targeting innate immune pathways, with a focus on natural killer (NK) cell checkpoints. Headquartered in Boston, with R&D operations in Bangalore, the company leverages its proprietary INABLR(R) platform-combining high-diversity human antibody libraries with yeast and phage display technologies, to rapidly advance differentiated biologics. Zumutor's lead asset, ZM008, a novel anti-LLT1 antibody, is currently in first-in-human clinical trials in the U.S., with dose expansion planned. The company is also progressing additional pipeline programs targeting NK cell activation pathways with strong oncology potential. Founded in 2015, Zumutor has raised approximately $33 million from a reputable global investor syndicate. Zumutor Contacts Kavitha Iyer Rodrigues: CEO, Zumutor Biologics Inc [email protected] About Coherus Oncology Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 ("PD-1") inhibitor, LOQTORZI(R)(toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company's strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of its two pipeline candidates in combination with LOQTORZI and through strategic partnerships. Coherus' innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma. LOQTORZI(R) is a registered trademark of Coherus Oncology, Inc.

Yahoo Finance
Mar 10th, 2026
Coherus Oncology doubles LOQTORZI revenue to $41M, slashes debt by 90% to $39M

Coherus Oncology has reported strong revenue growth for 2025, with its drug LOQTORZI achieving net revenue of $40.8 million, a 113% increase from $19.1 million in 2024. Fourth-quarter revenue reached $12.4 million, marking an 11% growth over the third quarter. The company significantly improved its financial position by reducing debt by over 90%, from $480 million to $38.8 million by year-end 2025. This resulted in interest cost savings of over $15 million. The firm also cut headcount by 35% and reduced selling, general and administrative expenses to $23.6 million in Q4 from $29.6 million the previous year. Coherus ended 2025 with $172.1 million in cash and investments whilst developing two promising product candidates, Tagmokitug and casdozokitug.

Yahoo Finance
Mar 8th, 2026
Coherus cuts debt 90%, LOQTORZI sales double in 2025, eyes $175M annual run rate by 2028

Coherus Oncology has reduced its debt by approximately 90%, cutting it from $480 million to $3.7 million in senior secured debt, whilst adding $250 million to its balance sheet through biosimilar asset divestitures following its 2023 Surface Oncology acquisition. The company reported accelerating sales of LOQTORZI, its PD-1 therapy for nasopharyngeal carcinoma, with 2025 sales doubling from 2024's $19 million. Management expects quarterly sales to reach $15 million to $16 million in 2026, covering the commercial team's costs, and projects a long-term run rate of roughly $175 million annually by 2028. Coherus aims to achieve cash-flow breakeven, excluding clinical trial costs, when quarterly sales exceed $30 million. The company has scheduled clinical data readouts for two pipeline assets in 2026.

MarketScreener
Feb 13th, 2026
Coherus Oncology prices $50M public offering at $1.75 per share to fund LOQTORZI commercialisation

Coherus Oncology has priced an underwritten public offering of 28.6 million shares of common stock at $1.75 per share. The company expects to raise approximately $50.1 million in gross proceeds before underwriting discounts and expenses. The offering includes a 30-day option for underwriters to purchase an additional 4.29 million shares. The transaction is expected to close on 17 February 2026. Coherus plans to use the net proceeds to support commercialisation of LOQTORZI, continue clinical development of product candidates, and for working capital and general corporate purposes. The commercial-stage oncology company has an approved PD-1 inhibitor and a pipeline targeting liver, prostate, head and neck, and colorectal cancers. TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunners.